What type of study is this?

This is a Human Clinical Trial study (also classified as: RCT).

What question did this study set out to answer?

This analysis aims to compare the risk of clinically relevant bleeding between apixaban and rivaroxaban during extended anticoagulation.

December 8, 2025Blood

Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial

View Full Paper

Ask AI

Bookmark

Authors

PGPhilippe GirardSaint-Gobain (France)OSOlivier SanchezInserm NMNicolas MéneveauSaint-Gobain (France)

Discussion

Member takes

Implication

Post hoc analysis finds similar bleeding risks for apixaban and rivaroxaban in VTE patients, suggesting both may provide effective extended treatment.

Key Points

This analysis aims to compare the risk of clinically relevant bleeding between apixaban and rivaroxaban during extended anticoagulation.
Post hoc analysis of a randomized controlled trial (RENOVE)
Compared full-dose vs reduced-dose anticoagulants in patients with venous thromboembolism
Measured cumulative incidence of clinically relevant bleeding among treatment groups
Adjusted hazard ratios for various confounding factors
5-year cumulative incidence of clinically relevant bleeding was 16.5% for apixaban vs 14.4% for rivaroxaban in full-dose groups
In reduced-dose groups, incidence was 11.0% for apixaban vs 9.0% for rivaroxaban
No significant difference in major bleeding between both drugs in either dosing group
Both drugs showed similar safety profiles across full- and reduced-dose subgroups

Cite This Study

Girard et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d314 https://doi.org/10.1182/blood-2025-740

View Full Paper

Ask AI

Bookmark

Implication

Post hoc analysis finds similar bleeding risks for apixaban and rivaroxaban in VTE patients, suggesting both may provide effective extended treatment.

Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Apixaban or rivaroxaban for extended anticoagulation in patients with venous thromboembolism: A post hoc analysis of the renove clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider